Sign Up for Email AlertsSign Up Today
A.G.P. / Alliance Global PartnersJames Molloy
Maxim GroupJason McCarthy, Ph.D
Synthetic Biologics, Inc. is a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. Our lead clinical candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, C. difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also advancing SYN-020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.View Profile
Synthetic Biologics, Inc.
Investor Relations Department
T: (301) 417-4364
Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, CO 80209
T: (303) 282-4800